Related Experiment Videos
Chemoprophylaxis for group B streptococcus transmission in neonates
1College of Pharmacy, University of Illinois at Chicago, USA.
Insights
Preventing Group B Streptococcus (GBS) transmission to newborns is crucial. Current guidelines recommend screening pregnant women and administering intrapartum chemoprophylaxis to those who test positive for GBS.
Area of Science:
- Obstetrics and Gynecology
- Neonatal Infectious Diseases
- Microbiology
Background:
- Group B Streptococcus (GBS) causes significant neonatal infections, with early-onset disease rapidly progressing and carrying a high mortality rate.
- Preventing GBS transmission is vital for reducing neonatal morbidity and mortality.
- Screening pregnant women for GBS colonization is recommended by the American Academy of Pediatrics (AAP).
Purpose of the Study:
- To review current guidelines and evidence regarding GBS screening and chemoprophylaxis in pregnant women.
- To highlight the importance of preventing neonatal GBS infections.
- To identify areas for future research, particularly concerning alternative antibiotic efficacy and vaccine development.
Main Methods:
- Review of current guidelines from the American Academy of Pediatrics (AAP) and the Centers for Disease Control and Prevention (CDC).
- Summary of recommended screening protocols, including timing and methods (vaginal/anorectal swabs, culture, rapid antigen testing).
- Outline of recommended intrapartum chemoprophylaxis regimens, including first-line (penicillin), alternatives (ampicillin), and options for penicillin-allergic patients (erythromycin, clindamycin).
Main Results:
- GBS infection affects 1.35-5.4 neonates per 1000 live births, with early-onset infections being particularly dangerous.
- Intrapartum penicillin is the recommended prophylaxis for GBS-positive pregnant women with risk factors.
- Ampicillin, erythromycin, and clindamycin serve as alternative treatments, though further large-scale studies on erythromycin and clindamycin efficacy are needed.
Conclusions:
- Current chemoprophylaxis strategies are effective in preventing early-onset GBS infections.
- Prompt treatment with ampicillin and gentamicin is recommended for late-onset GBS infection.
- Development of GBS vaccines for maternal administration holds promise as a future preventive measure.
Abstract:
GBS causes infection in 1.35-5.4 neonates per 1000 live births. Early-onset GBS infection in neonates develops rapidly and has a high mortality rate. Preventing the transmission of GBS to neonates is of considerable value to avert neonatal morbidity and mortality. Although some controversy exists regarding who should receive chemoprophylaxis and when, AAP guidelines suggest that all pregnant women be screened between 26 and 28 weeks' gestation for GBS colonization by obtaining swabs form vagina and anorectal areas and culturing them or testing by rapid antigen test. According to the latest guidelines from the CDC, any pregnant woman who tests positive for GBS and who has one or more risk factors should be given intrapartum penicillin 5 million units i.v. as the first dose and then 2.5 million units q6h until delivery. Ampicillin, in a dosage of 2 g as the first dose and then 1 g every 4-6 hours may be used as an alternative. Patients who are allergic to penicillin can be given either erythromycin 500 mg i.v. q6h or clindamycin 600 mg i.v. q8h. The chemoprophylaxis is primarily effective for early-onset GBS infection; for late-onset infection, aggressive treatment of the neonate should be initiated promptly with ampicillin and gentamicin. Although many studies have been published that establish the efficacy of ampicillin for intrapartum GBS prophylaxis, there is a need for large-scale studies to show the efficacy of both erythromycin and clindamycin. Various vaccines are under development for maternal administration to prevent the transmission of GBS to neonates. When one is available, it will be an added weapon against GBS.